Articles By Jack Cush, MD
5 Mistakes When Diagnosing Adult-Onset Still’s Disease
Adult-onset Still's posses a interestng and diagnostic challeng when encountered. Here are 5 tips to improve your diagnostic acumen for this febrile disorder.
Read ArticleThe Best Kind of Arthritis
I was recently asked, “what is the best kind of arthritis to have?” My response is based on diagnosibility, treatability and safety of necessary treatment.
Read ArticleThe Evolution of Drug Safety
Drug efficacy is swiftly proven in phase II and III trials. Yet drug safety requires time, wider exposure, physician education and patient acceptance to be fully established.
Read Article
DECT Evidence of Urate Deposition is Associated with X-ray Damage in Gout
Dalbeth and coworkers studied 92 patients with gout and using DECT scanning have shown those with urate deposition on DECT were 8.5-fold more likely to have erosive disease on plain radiographs.
Read Article
Nonadherence to Self-Injected Biologics is High
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Read Article
Osteoporosis Induced by Bariatric Surgery
Although the cause is not clear, women who have weight loss surgery have a higher risk of thinning bones (osteoporosis) and fractures over time, according to a new analysis of a Swedish study.
Read Article
Medicare D and Costly Biologics
25% of Medicare beneficiaries with rheumatoid arthritis use high-cost biologics. Yazdany and coworkers have analyzed a national cohort of beneficiaries and compared Medicare part D plans.
Read Article
Prevalence of doctor-diagnosed arthritis and activity limitations
52.5 million US adults (22.7%) have arthritis with half of these claiming activity limitation because of arthritis and pain. Many arthritis patients have comorbid conditions including heart disease (49%), diabetes (47%) and obesity (31%).
Read Article
Annual Review of Rheumatology Advances - 2014
This retrospective highlights several of the most impactful publications, trends, research and news that occurred in 2014.
Read Article
Amgen Halts Development of Brodalumab
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
Read Article